Comparison of (R) and (S) Propafenone for Prevention of Atrial Fibrillation Induction
A double-blind randomized active-controlled clinical trial that will determine the efficacy of R-propafenone for suppressing inducible atrial fibrillation in patients with a history of paroxysmal AF undergoing ablation. This is a single center study conducted at Vanderbilt University Medical Center by VanCART members Knollmann and Shoemaker.
Arrhythmia Genetics Network (AGENT) - Vanderbilt Cohort
Multicenter observational registry and DNA biorepository for inherited arrhythmia syndromes. Currently participating centers: Vanderbilt, MGH, U of Washington, Stanford, Cedars Sinai.
GS-6615 Late Sodium Current Blocker for Long QT Type 3
Phase 3 clinical trial of GS-6615 to reduce QT interval in LQT3 patients. This is a study conducted at Vanderbilt University by VanCART member M. Benjamin Shoemaker, MD, MSCI.
Multicenter observational study of activity level (measured by Fitbit) and arrhythmic events in LQTS (PI: Rachel Lampert (Yale) http://livelqts.org/ )
A New Paradigm for Identifying Patients and Drugs at Risk for QT Prolongation (Improving Prediction of Drug Action- PGRN IV
A current project of PGRN that will create iPSC-derived cardiomyocytes from patients with a history of drug-induced TdP.
The Vanderbilt AF Electrophysiology Phenotyping Project
A prospective observational registry with DNA and EP data from patients with AF undergoing AF ablation. Standardized data collection includes: baseline intervals, AV block cycle length, AV node ERP, LA ERP, pulmonary vein ERP, LA voltage, LA conduction velocity, and PV myocardial sleeve measurements.